Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2021-11-03

FDA Approved: ROZEREM — Supplemental Application (Takeda Pharmaceuticals America, Inc.)

View source ↗

Summary

The FDA approved a supplemental application for ROZEREM (ramelteon) from Takeda Pharmaceuticals America, Inc.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • ROZEREM (ramelteon)

Snippet

SUPPL AP for ROZEREM (RAMELTEON)